


Claims

1. Use of a compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein

R is selected from the group consisting of hydrogen, phenylsulfanyl, 2-hydroxy-naphthalen-1-yl, quinolin-8-ylsulfanyl, triazol-3-yl sulfanyl, and benzothiazol-2-ylsulfanyl;

R¹ is selected from the group consisting of hydrogen, methyl, chloro, bromo, methoxy, ethoxy, tert-butyl, nitro, methyl ester, acetamide, 1,4 dioxine, fluoro, trifluoro methoxy, acetyl, trifluoro methyl, propyl, cyclohexene, methoxy-phenoxy, chloro phenoxy, tolyloxy, and phenoxy,

in the manufacturing of a medicament for treating, reducing the risk of recurrence of, or preventing recurrence of cancer in a subject in need thereof, wherein the use further comprises an immune checkpoint inhibitor, and wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof is for oral administration.

2. The use of claim 1, wherein the compound of Formula (I) inhibits signal transducer and activator of transcription 3 (STAT3).

3. The use of claim 1, wherein the compound of Formula (I) is N-(1',2'-dihydroxy-1,2'-binaphthalen-4'-yl)-4-methoxybenzenesulfonamide, N-(3,1'-Dihydroxy-[1,2']binaphthalenyl-4'-yl)-4-methoxy-benzenesulfonamide, N-(4,1'-Dihydroxy-[1,2']binaphthalenyl-4'-yl)-4-methoxy-benzenesulfonamide, N-(5,1'-Dihydroxy-[1,2']binaphthalenyl-4'-yl)-4-methoxy-benzenesulfonamide, N-(6,1'-Dihydroxy-[1,2']binaphthalenyl-4'-yl)-4-methoxy-benzenesulfonamide, N-(7,1'-Dihydroxy-[1,2']binaphthalenyl-4'-yl)-4-methoxy-benzenesulfonamide, N-(8,1'-Dihydroxy-[1,2']binaphthalenyl-4'-yl)-4-methoxy-benzenesulfonamide, 4-Bromo-N-(1,6'-dihydroxy-[2,2']binaphthalenyl-4-yl)-benzenesulfonamide, or 4-Bromo-N-[4-hydroxy-3-(1H-[1,2,4]triazol-3-ylsulfanyl)-naphthalen-1-yl]-benzenesulfonamide, or a pharmaceutically acceptable salt thereof.

4. The use of claim 3, wherein the compound of Formula (I) is N-(1',2'-dihydroxy-1,2'-binaphthalen-4'-yl)-4-methoxybenzenesulfonamide.

5. The use of claim 1, wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.

6. The use of claim 5, wherein the PD-1 inhibitor is an anti-PD-1 antibody.
7. The use of claim 6, wherein the anti-PD-1 antibody is cemiplimab, nivolumab, pembrolizumab, pidilizumab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, sasanlimab, retifanlimab, tebotelimab, ABBV-181, AK104, AK105, BCD-100, BI-754091, CBT-501, CC-90006, GLS-010, HLX10, IBI-308, JNJ-3283, JS001, LZM009, MEDI0680 (AMP-514), REGN-2810, SHR-1210, Sym021, TSR-042, or XmAb20717.
8. The use of claim 7, wherein the anti-PD-1 antibody is pembrolizumab.
9. The use of claim 5, wherein the PD-L1 inhibitor is an anti-PD-L1 antibody.
10. The use of claim 9, wherein the anti-PD-L1 antibody is atezolizumab, avelumab, durvalumab, envafolelimab, FS118, BCD-135, BGB-A333, BGBA-317, CBT-502, CK-301, CS1001, FAZ053, MDX-1105, MSB2311, SHR-1316, M7824, LY3415244, CA-170, or CX-072.
11. The use of claim 9, wherein the anti-PD-L1 antibody is atezolizumab.
12. The use of any one of claims 1-11, wherein the immune checkpoint inhibitor is to be administered prior to administration of the compound of Formula (I).
13. The use of any one of claims 1-11, wherein the immune checkpoint inhibitor is to be administered concomitantly with administration of the compound of Formula (I).
14. The use of any one of claims 1-11, wherein the immune checkpoint inhibitor is to be administered subsequently to administration of the compound of Formula (I).
15. The use of any one of claims 1-14, wherein after three weeks or more of administration of the compound of Formula (I) and the immune checkpoint inhibitor, the subject has at least a partial remission.
16. The use of any one of claims 1-15, wherein after six weeks or more of administration of the compound of Formula (I) and the immune checkpoint inhibitor, the subject has complete remission.
17. The use of any one of claims 1-16, wherein the use reduces tumor size by at least 20% more within six weeks of administration relative to a subject administered immune checkpoint inhibitor alone.
18. The use of any one of claims 1-17, wherein the immune checkpoint inhibitor is to be administered parenterally.
19. The use of any one of claims 1-18, wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, prostate

cancer, cervical cancer, brain cancer, pancreatic cancer, myelodysplastic syndrome, neuroblastoma, kidney cancer, or metastatic melanoma.

20. The use of claim 19, wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, or pancreatic cancer.